[1]
|
Japanese Society for Dialysis Therapy (2008) An overview of regular dialysis treatment in Japan. Japanese So- ciety for Dialysis Therapy, Tokyo.
|
[2]
|
Shinzato, T., Narita, S., Akiba, T., et al. (1999) Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney International, 55, 700- 712. doi:10.1046/j.1523-1755.1999.00297.x
|
[3]
|
Weiner, D.E., Tighiouart, H., Amin, M.G., et al. (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. Journal of the American Society of Nephrology, 15, 1307-1315.
doi:10.1097/01.ASN.0000123691.46138.E2
|
[4]
|
Jafar, T.H., Stark, P.C., Schmid, C.H., et al. (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Annals of Internal Medicine, 139, 244-252.
|
[5]
|
Koyama, A., Igarashi, M. and Kobayashi, M. (1997) Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research group on progressive renal diseases. American Journal of Kidney Diseases, 29, 526-532. doi:10.1016/S0272-6386(97)90333-4
|
[6]
|
Goto, M., Wakai, K., Kawamura, T., et al. (2009) A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective chhort study. Nephrology, Dialysis Transplantation, 24, 3068-3074.
doi:10.1093/ndt/gfp273
|
[7]
|
Alamartine, E., Sabatier, J.C., Guerin, C., Berliet, J.M. and Berthoux, F. (1991) Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses. American Journal of Kidney Diseases, 18, 12-19.
|
[8]
|
D'Amico, G. (2000) Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. American Journal of Kidney Diseases, 36, 227- 237. doi:10.1053/ajkd.2000.8966
|
[9]
|
Chauveau, D. and Droz, D. (1993) Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contribution to Nephrology, 104, 1-5.
|
[10]
|
Tomino, Y. and Sakai, H. (2003) Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clinical and Experimental Nephrology, 7, 93-97.
doi:10.1007/s10157-003-0232-4
|
[11]
|
Woolhandler, S., Pels, R.J., Bor, D.H., Himmelstein, D.U. and Lawrence, R.S. (1989) Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. The Jouranl of the American Medical Association, 262, 1214-1219.
|
[12]
|
Yamagata, K., Ishida, K., Sairenchi, T., et al. (2007) Risk factors for chronic kidney disease in a community-based population: A 10-year follow-up study. Kidney International, 71, 159-166. doi:10.1038/sj.ki.5002017
|
[13]
|
Yamagata, K., Takahashi, H., Tomida, C., Yamagata, Y. and Koyama, A. (2002) Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron, 91, 34-42.
doi:10.1159/000057602
|
[14]
|
Maeda, A., Gohda, T., Funabiki, K., Horikoshi, S., Shirato, I. and Tomino, Y. (2003) Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. Journal of Clinical Laboratory Analysis, 17, 73-76. doi:10.1002/jcla.10071
|
[15]
|
Nakayama, K., Ohsawa, I., Maeda-Ohtani, A., et al. (2008) Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. Journal of Clinical Laboratory Analysis, 22, 114-118.
doi:10.1002/jcla.20227
|
[16]
|
Moldoveanu, Z., Wyatt, R.J., Lee, J.Y., et al. (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney International, 71, 1148-1154. doi:10.1038/sj.ki.5002185
|